CAR T cells have revolutionized the treatment of certain blood cancers, but they often fail. A new study published in Nature (DOI: 10.1038/s41586-025-09507-9) by scientists at CeMM and the Medical University of Vienna introduces a novel CRISPR screening platform, which discovered unexpected genetic edits that make CAR T cells more effective as cancer therapies.